Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment.

Rosoux, Adeline;Duplaquet, Fabrice;Ocak, Sebahat
(2017) Case Reports in Oncology — Vol. 10, n° 2, p. 447-451 (2017)

Files

RosouxACaseRepOncol2017.pdf
  • Restricted Access
  • Adobe PDF
  • 581.71 KB
Request a copy

Details

Authors
Abstract
Crizotinib is an approved tyrosine kinase inhibitor in the treatment of advanced-stage non-small-cell lung cancer patients with anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement. Renal dysfunction after crizotinib administration was recently reported, but the physiopathological explanation and the safety in patients with preexisting renal dysfunction are still not clear.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Rosoux, A., Duplaquet, F., & Ocak, S. (2017). Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment. Case Reports in Oncology, 10(2), 447-451. https://doi.org/10.1159/000475755 (Original work published 2017)